Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company whose news flow reflects its role in life science tools, bioactive reagents, diagnostics, and spatial biology. Company announcements frequently highlight financial results, product launches, collaborations, and participation in healthcare and investor conferences, giving investors and researchers insight into how Bio-Techne is executing its strategy.
Recent press releases include quarterly and annual financial updates, where Bio-Techne reports net sales, segment performance for its Protein Sciences and Diagnostics and Spatial Biology segments, and commentary on market conditions. These earnings communications often discuss organic revenue trends, operating margins, and portfolio decisions such as divestitures of non-core businesses.
Product and technology news from Bio-Techne covers launches of analytical instruments, spatial biology assays, and multiomic workflows. Examples include announcements of next-generation protein analysis systems with multiplexing capabilities, spatial biology platforms that combine RNA and protein detection, and assays that visualize protein-protein interactions within tissue at subcellular resolution. Such updates show how the company is expanding its proteomic analytical tools and spatial biology offerings, which it identifies as growth pillars.
Bio-Techne also issues news about strategic collaborations and licensing agreements. Recent items describe partnerships in AI-enabled protein design, multiomic spatial analysis with academic and industry partners, and initiatives supporting cell and gene therapy manufacturing workflows. In addition, the company regularly announces its participation in major healthcare and investor conferences, where management presents its outlook and strategy.
This TECH news page aggregates these types of updates so readers can follow Bio-Techne’s financial reporting, product innovation, strategic partnerships, and conference activity in one place. Investors, analysts, and scientists can use this feed to monitor developments across the company’s life science tools, diagnostics, and spatial biology businesses.
Bio-Techne Corporation (NASDAQ: TECH) will be presenting at the Stephens Annual Investment Conference 2020 on November 17, 2020, at 3:00 p.m. EST. Chuck Kummeth, President and CEO, will lead the presentation, which will be available via a live webcast on the company's Investor Relations website.
In fiscal 2020, Bio-Techne generated approximately $739 million in net sales and employs over 2,300 people globally. The company specializes in developing high-quality proteins, diagnostic products, and genomic tools essential for scientific research and clinical diagnostics.
Bio-Techne Corporation (NASDAQ: TECH) has declared a quarterly dividend of $0.32 per share for the period ending September 30, 2020. This dividend is payable on November 27, 2020 to shareholders on record as of November 16, 2020. The company reported approximately $739 million in net sales for fiscal 2020 and employs over 2,300 people worldwide. Future dividends will be assessed quarterly by the Board of Directors.
Bio-Techne Corporation (NASDAQ:TECH) reported a robust first quarter for FY2021, ending September 30, with organic revenue growth of 10%, totaling $204.2 million. The GAAP EPS rose to $0.83 from $0.37 year-on-year, while adjusted EPS saw a 35% increase to $1.43. The Diagnostics and Genomics segment achieved 17% organic growth, bolstered by the launch of a new GMP manufacturing facility. Despite challenges from COVID-19, a positive long-term outlook is anticipated due to increased funding in life sciences.
Bio-Techne Corporation (NASDAQ: TECH) will have its CEO, Chuck Kummeth, present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 1:20 p.m. EST. Interested parties can access a live webcast through the Investor Relations website. Bio-Techne specializes in producing high-quality proteins and diagnostic tools used in biomedical research and clinical laboratories. In fiscal 2020, the company reported approximately $739 million in net sales and employs over 2,300 people globally.
Bio-Techne Corporation (NASDAQ: TECH) announced that CFO Jim Hippel will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on November 11, 2020, at 4:15 p.m. EST. Interested parties can access the live webcast through the company's Investor Relations website. Bio-Techne specializes in high-quality purified proteins, reagents, and diagnostic products, generating approximately $739 million in net sales in fiscal 2020. With over 2,300 employees, Bio-Techne continues to support scientific research, drug discovery, and clinical diagnostics.
Kantaro Biosciences has formed a two-year marketing and distribution agreement with EKF Diagnostics to provide its COVID-19 antibody tests, COVID-SeroKlir and COVID-SeroIndex, across Europe, with exclusive rights in the UK and Germany. The tests boast a CE Mark certification, demonstrating high sensitivity (97.8%) and specificity (99.6%) in detecting IgG antibodies. This partnership aims to enhance public health strategies and assist in assessing immunity amidst ongoing vaccination efforts. The technology is based on extensive research at the Mount Sinai Health System.
Kantaro Biosciences, in partnership with Bio-Techne Corporation, has secured CE marking for its COVID-SeroKlir and COVID-SeroIndex antibody test kits. These quantitative tests, now available to authorized clinical labs in the EU, provide crucial data about COVID-19 antibody presence and levels. COVID-SeroKlir demonstrates 97.8% sensitivity and 99.6% specificity, supporting both clinical and research applications. Kantaro aims to produce up to 10 million tests monthly, enhancing pandemic response efforts.
Bio-Techne Corporation (NASDAQ: TECH) launched the SARS-CoV-2 Multi-Antigen Serology Module for its Simple Western automated systems. This new assay detects human IgG antibodies against five SARS-CoV-2 antigens within three hours, processing up to 23 samples simultaneously. The module promises to enhance COVID-19 research by providing a detailed view of immune responses, offering quicker, reproducible results compared to traditional methods. Bio-Techne emphasizes its commitment to supporting vaccine developers and researchers with this advanced technology.
Summary not available.
Bio-Techne Corporation (NASDAQ: TECH) will host a conference call and webcast on November 5, 2020, at 8:00 a.m. CST to discuss its first quarter 2021 financial results. Investors can access the live call via phone or online. A replay will be available after the call until December 5, 2020. Bio-Techne, a leader in developing purified proteins and diagnostic products, reported approximately $739 million in net sales for fiscal 2020 and employs around 2,300 staff worldwide.